Histone deacetylase class II and acetylated core histone immunohistochemistry in human brains with Huntington’s disease
Authors:
- Daniel YoungDYDaniel Young
- Juri G. GelovaniJGJuri G. Gelovani
- Andrew RobinsonARAndrew Robinson
- Yvonne DavidsonYDYvonne Davidson
- Karl HerholzKHKarl Herholz
- David M.A. MannDMDavid M.A. Mann
- 1 April 2013
- journal article
- Published by Elsevier in Brain Research
- Vol. 1504, 16-24
Abstract
No abstract availableKeywords
Funding Information
- Alzheimer’s Research UK
- Alzheimer's Society
- Alzheimer’s Research UK
- Alzheimer's Society
This publication has 20 references indexed in Scilit:
- Disruption of Purkinje cell function prior to huntingtin accumulation and cell loss in an animal model of Huntington DiseaseExperimental Neurology, 2012
- Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disordersCurrent Opinion in Pharmacology, 2008
- Histone Deacetylase 6 Inhibition Compensates for the Transport Deficit in Huntington's Disease by Increasing Tubulin AcetylationThe Journal of Neuroscience, 2007
- Distribution of histone deacetylases 1–11 in the rat brainJournal of Molecular Neuroscience, 2007
- Histone deacetylase inhibitors as therapeutics for polyglutamine disordersNature Reviews Neuroscience, 2006
- Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17Nature, 2006
- Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease MiceThe Journal of Neuroscience, 2003
- Histone deacetylase activity is retained in primary neurons expressing mutant huntingtin proteinJournal of Neurochemistry, 2003
- Neuronal activity‐dependent nucleocytoplasmic shuttling of HDAC4 and HDAC5Journal of Neurochemistry, 2003
- Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's diseaseProceedings of the National Academy of Sciences, 2003